Carryover effects were not formally tested, given the >6-day washout between trials and that there were no differences in baseline biochemical, anthropometric, dietary, or physical activity measures before each intervention (Table 1) (26, 31).
Patients and volunteers received a single oral dose of 25 mg of telapristone acetate (fasted) followed by 50 mg of telapristone acetate (fasted) after a 14-day washout period (Trial identification number: NCT00741273).
In this study, 6 normal New Zealand white rabbits were used in a random crossover design (4 × 4 Latin square) with a 1-week washout period between trials.
This, however, did not constitute a washout effect between trials.
Consenting participants who underwent an OGTT at their last study visit, who had not developed diabetes, and who were taking their study medication were entered into the post-trial washout.
In the case of duloxetine, and in contrast to most other trials, a washout of previous NSAIDs was not enforced.
Glycemic status was analyzed for the trial plus washout period and for the washout period alone.
No statistical interactions were observed between ramipril and rosiglitazone with respect to FPG levels, 2-h plasma glucose levels, or glycemic status at the end of the trial plus washout or during the washout period alone.
Furthermore, inclusion of washout periods in our trial revealed a change of blood pressure over time independent of treatment, suggesting that blood pressure median values regressed towards the mean over the 24 week (6 month) study period.
Thirty men and women (age 30 ± 8 year, body mass 72.9 ± 17.1 kg, body fat 13.0 ± 6.4%) participated in 2 vascular testing days, each preceded by 3 weeks of supplementation with either 2 g/day of l-Carnitine (l-Carnitine l-Tartrate) or placebo with a 3- to 5-week washout period between trials.
